Gaurav Shah, CEO of Rocket Pharmaceuticals (NASDAQ:RCKT), has reported recent stock transactions in a Form 4 filing with the SEC on May 26, 2026, for activity on May 21, 2026.
Shah sold 55,684 shares of common stock for a total value of approximately $171,840. The shares were sold in multiple transactions at prices ranging from $3.08 to $3.105 per share to cover the exercise price of a stock option and related taxes.
Prior to the sale, Shah acquired 76,490 shares through the exercise of a stock option at an exercise price of $1.691 per share, valued at approximately $129,344. The option was exercised ahead of its expiration on April 12, 2027.
Following these transactions, Shah directly holds 1,061,724 shares of common stock. RCKT shares traded at $2.99, down 52% over the past year. Bond.az analysis suggests the stock appears undervalued at current levels, with a market cap of $328 million.
Additionally, Shah indirectly holds 207,897 shares through his spouse and 198,341 shares through the Gaurav D. Shah Irrevocable Trust.
In other news, Rocket Pharmaceuticals recently sold its Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway into Q2 2028. Analysts have responded positively: Leerink Partners raised its price target to $12.00, and BofA Securities raised its target to $9.00, both maintaining a Buy rating.
